HC Wainwright has reduced its price target on Foghorn Therapeutics (NASDAQ:FHTX) from $13.00 to $5.00 while maintaining a Buy rating, reflecting a major strategic shift for the clinical-stage biotechnology company. The adjustment follows a cascade of pipeline setbacks, leadership decisions to terminate a high-profile pharmaceutical collaboration, and a sweeping corporate restructuring.
Cambridge, Massachusetts-based Foghorn Therapeutics develops medicines using its Gene Traffic Control discovery platform to target the chromatin regulatory system. However, recent clinical reviews and broader market reactions have triggered widespread analyst downgrades, valuation pressures, and a significant contraction in share price.
What Changed in the Foghorn Therapeutics Pipeline
The downward revision by HC Wainwright and concurrent actions across Wall Street follow a critical partnership update. Foghorn Therapeutics and Lilly decided not to advance FHD-909 (LY4050784) into clinical expansion following a review of Phase 1 dose-escalation data. Additionally, both companies decided not to advance the selective SMARCA2 degrader program.
The termination completely eliminates Lilly’s ongoing collaboration with Foghorn Therapeutics. To offset the loss of partner backing and realign its operational footprint, Foghorn Therapeutics announced plans to reduce its workforce by approximately 40% as part of a comprehensive restructuring and strategic reset.
Management expects the restructuring and workforce reduction to extend the company’s cash runway into the second half of 2029. Despite these measures, the discontinuation of partnered programs has altered the company’s risk profile, leading major financial institutions to reassess their positions.
Analyst Ratings and Market Reactions
Financial institutions have responded swiftly to the pipeline changes and corporate downsizing. Alongside HC Wainwright’s target cut to $5.00—which still implies a potential upside of 147.52% from the stock’s previous close—Stifel Nicolaus set a matching $5.00 target price on Foghorn Therapeutics shares.
Other major firms adopted a more defensive stance. TD Cowen downgraded Foghorn Therapeutics from Buy to Hold, while BTIG Research lowered its rating from Buy to Neutral. Citigroup similarly lowered its rating from Market Outperform to Market Perform. Meanwhile, Weiss Ratings reiterated a Sell (d-) rating on July 17th.
According to analyst ratings tracked by MarketBeat, Foghorn Therapeutics holds four Buy ratings, five Hold ratings, and one Sell rating, resulting in an average rating of Hold and an average price target of $6.67.
Financial Performance and Stock Performance
Market pressures have weighed heavily on NASDAQ:FHTX shares. Following the operational announcements, shares of FHTX opened at $2.02, marking a single-session decline of 30.8%.
Foghorn Therapeutics carries a 12-month low of $1.79 and a 12-month high of $7.61, with a total market capitalization of $119.95 million. The company reports a price-to-earnings ratio of -2.06 and a beta of 3.01. Its 50-day simple moving average sits at $5.11, while its 200-day simple moving average rests at $4.82.
On the financial front, Foghorn Therapeutics reported earnings per share of -$0.10 for the quarter reported on August 6th, beating analyst consensus estimates of -$0.24. Quarterly revenue reached $16.07 million, outpacing expectations of $6.80 million. Sell-side analysts currently expect Foghorn Therapeutics to post -0.85 EPS for the current fiscal year.
Institutional Ownership and Investor Sentiment
Despite the sharp drop in share price and ongoing clinical transitions, institutional investors and hedge funds maintain a substantial stake, owning 61.55% of Foghorn Therapeutics’ stock.
Recent institutional purchasing activity includes positions from Diversified Trust Co ($52,000 in Q1), Canada Pension Plan Investment Board (about $122,000 in Q2), Bank of America Corp DE (approximately $127,000 in Q2), GSA Capital Partners LLP (approximately $144,000 in Q2), and Deutsche Bank AG (approximately $178,000 in Q2).
Future Outlook and Strategic Priorities
With the Lilly collaboration terminated, Foghorn Therapeutics plans to pivot its focus toward its wholly owned pipeline. This internal portfolio includes selective EP300 and CBP degraders, an oral immunology and inflammation program, and an induced-proximity platform.
Analyst revisions from firms like TD Cowen, BTIG, and Stifel reflect heightened uncertainty regarding Foghorn Therapeutics’ clinical pipeline and future catalysts following Lilly’s exit. Whether the restructuring and workforce reduction will successfully extend the cash runway into the second half of 2029 as management expects remains a key focal point for market observers, alongside the clinical execution of the company’s remaining wholly owned assets.